A. Keith Stewart, MB, ChB
Carlson and Nelson Endowed Medical Director, Mayo Clinic Center for Individualized Medicine
Dr. Keith Stewart is a consultant in the Division of Hematology/Oncology at Mayo Clinic; and recognized as the Vasek and Anna Maria Polak Professor of Cancer Research.
Dr. Stewart received an M.B., Ch.B. degree at Aberdeen University Medical School in the United Kingdom; and an MBA degree at the University of Western Ontario.
He has more than 20 years of sustained national funding for laboratory research programs focusing on genomics and individualized treatment of multiple myeloma; and has led numerous clinical trials for multiple myeloma.
Dr. Stewart serves as Dean for Research in Arizona and is a member of the Arizona Executive Operations Team and Clinical Practice Committee.
Dr. Stewart has authored more than 250 publications and was an associate editor for Blood from 2009-2014. He has served on multiple national committees and advisory boards recently, including the National Cancer Institute Experimental Therapeutics Study Section Chair; the Medical and Scientific Advisory Board of the Leukemia & Lymphoma Society; and the Investment and Audit Committee of the American Society of Hematology.
Minnesota Public Radio
Bio coming soon.
C. Anthony Altar, Ph.D.
Senior Vice President, Neuroscience
Dr. C. Anthony Altar is an early member of AssureRx Health, Inc. As Senior Vice President, Neurosciences, he is responsible for the research of pharmacogenomic products.
Before joining the Assurex Health, Inc., team, Dr. Altar directed the Alzheimer's Diagnostic Laboratory for the Blanchette Rockefeller Neuroscience Institute. Dr. Altar earned a B.S. with Honors in Psychobiology from UCLA and a Ph.D., with Honors in Psychology from UC Santa Barbara.
As a postdoctoral scientist at UC Irvine, Dr. Altar created digital imaging of receptor-drug binding in the brain and while at UC Irvine, and Ciba-Geigy, he identified the serotonin/dopamine receptor binding profile of atypical antipsychotics. At Genentech and Regeneron Pharmaceuticals, Dr. Altar pioneered research of neurotrophic factors, and was the first to discover roles for BDNF in serotonin function, pain, and depression.
As global director for neuroscience at Otsuka, Dr. Altar led the team that discovered Abilify, its likely uses in psychosis, depression and bipolar illness, and helped lead the effort in its FDA approval. His teams at Psychiatric Genomics Inc. used genomics to discover the insulin-deficiency of schizophrenia and validated drug targets for this approach. He launched the Biomarkers Consortium within the Foundation for NIH.
Dr. Altar has published 135 neuroscience and drug discovery articles in peer-reviewed journals including Science and Nature.
Stephen Ansell, M.D., Ph.D.
Professor of Medicine, Mayo Clinic
Dr. Stephen Ansell is a consultant in the Division of Hematology, Department of Internal Medicine at Mayo Clinic. He holds the academic rank of Professor of Medicine, Mayo Clinic College of Medicine. Dr. Ansell received his M.D. and Ph.D. at the University of Pretoria, South Africa and trained in Medical Oncology before coming to the United States. Dr. Ansell completed a residency in Internal Medicine and a fellowship in Hematology and Oncology at Mayo Clinic.
Dr. Ansell’s clinical practice interests focus on non-Hodgkin lymphoma, Hodgkin’s disease, and Waldenstrom’s macroglobulinemia. His research focuses on the biology of the disease, and on developing new therapies. He receives funding for research from the National Institutes of Health, the Leukemia and Lymphoma Society, and the International Waldenstrom’s Macroglobulinemia Foundation.
Dr. Ansell is Chair of the Mayo Clinic Lymphoma Group as well as Chair of the Faculty Development and Recruitment for Hematology at Mayo Clinic. He has been honored with various awards, including the Department of Medicine New Investigator at Mayo Clinic and Medical Honoree at the Lymphoma Research Foundation, Minnesota Chapter. He held memberships with the American Association for Cancer Research, the American Medical Association, the American Society of Clinical Oncology, and the Eastern Cooperative Oncology Group.
Dr. Ansell has served on the editorial boards of the American Journal of Hematology, Journal of Clinical Oncology, Blood Cancer Journal and Clinical Lymphoma and Myeloma. He has co-authored more than 234 articles in peer-reviewed journals.
Paldeep Atwal, M.D., MRCP (UK)
Medical Director, Center for Individualized Medicine, Mayo Clinic
Dr. Paldeep Atwal is a clinical, and medical biochemical geneticist and Medical Director of the Center for Individualized Medicine for Mayo Clinic in Florida. He received his M.D. from the University of Glasgow, and trained in hospital internal medicine with The Royal College of Physicians at Glasgow Royal Infirmary in Scotland. He received diplomas in structural molecular biology, and forensic medical science, and completed a genetics fellowship at Stanford University, and a biochemical genetics fellowship at Baylor College of Medicine where he was involved in developing a clinical metabolomic profiling test.
Dr. Atwal’s clinical interests include medical genetics, undiagnosed diseases following lengthy diagnostic odysseys, and inborn errors of metabolism including mitochondrial diseases. He has a long standing interest in rare, and undiagnosed disease including the use of multiple concurrent –omics platforms to provide a diagnosis to patients.
Dr. Atwal’s honors include the 2014-2015 ACMG Foundation/Genzyme Fellowship in Biochemical Genetics Award and The Neurobiology of Disease in Children Young Investigator Award.
Matthew Bernard, M.D.
Associate Professor and Chair of Family Medicine, Mayo Clinic
Dr. Matthew Bernard is an Associate Professor and Chair of the Department of Family Medicine at Mayo Clinic. Dr. Bernard received his M.D. from the University of Minnesota School of Medicine, and completed his Family Medicine residency training at the Mayo School of Graduate Education.
Dr. Bernard has an interest in the education of clinicians on how to practically integrate genomic information into clinical practice. He has developed continuing medical education conferences on genomic medicine in clinical practice.
Robert Bradley, Ph.D.
Assistant Member in the Computational Biology Program, Public Health and Basic Sciences Division, Fred Hutchinson Cancer Research Center
Dr. Robert Bradley is an Assistant Member in the Computational Biology Program, Public Health Sciences Division, and Basic Sciences Division at Fred Hutchinson Cancer Research Center in Seattle, Washington. Dr. Bradley received a Ph.D. in Biophysics from the University of California, Berkeley, and completed postdoctoral training at the Massachusetts Institute of Technology.
Dr. Bradley studies RNA biology in human disease, with a focus on identifying new roles for abnormal RNA processing in disease initiation and therapeutic response. Two areas of current interest are mutations affecting RNA splicing factors in myelodysplastic syndromes and nonsense-mediated decay in facioscapulohumeral muscular dystrophy. He is broadly interested in methods to combine and analyze high-throughput sequencing data from research, and clinical settings.
Dr. Bradley’s honors include the New Scholar Award from the Ellison Medical Foundation, and the Dale F. Frey Award from the Damon Runyon Cancer Research Foundation.
Richard Caselli, M.D.
Professor of Neurology, Mayo Clinic College of Medicine
Dr. Richard Caselli is Professor of Neurology in the Mayo Clinic College of Medicine, Associate Director for the Center for Individualized Medicine in Arizona, Associate Director of the Arizona Alzheimer’s Disease Center, and Director of the Clinical Core coordinating the clinical participation of its six member institutions. In addition, he serves on the Alzheimer’s Prevention Initiative committee on genetic disclosure for the upcoming APOE e4 homozygote disease prevention trial.
His earlier appointments included Chair of the Department of Neurology from 2000 to 2010, and member of the Mayo Clinic in Arizona Board of Governors from 2002-2010.
Dr. Caselli’s research programs include cognitive aspects of aging, Alzheimer’s disease, and other forms of dementia. Particular emphasis is focused on the way genetic risk factors for dementia influence how the mind changes with age before the onset of memory loss, and dementia including the preclinical effects of APOE e4 on cognitive aging patterns, and how they differ between healthy aging and preclinical Alzheimer’s disease.
Dr. Caselli received the Mayo Clinic Arizona Distinguished Clinician and Distinguished Investigator Awards, as well as the Lifetime Educator Award.
Wendy Chung, M.D., Ph.D.
Herbert Irving Associate Professor of Pediatrics and Medicine Director of Clinical Genetics, Columbia University
Dr. Wendy Chung is associate professor of pediatrics and medicine, and director of the clinical genetics program at Columbia University. She received her B.A. in biochemistry and economics from Cornell University, her M.D. from Cornell University Medical College, and her Ph.D. from The Rockefeller University in genetics.
Dr. Chung’s research focuses on the integration of genetic medicine into all areas of health care. She directs NIH funded research programs in human genetics of obesity, breast cancer, pulmonary hypertension, and birth defects including congenital diaphragmatic hernia, and congenital heart disease.
She was the original plaintiff in the Supreme Court case that overturned the ability to patent genes and is a member of the National Advisory Council for Human Genome Research, and the Genomics & Society Working Group. She has authored over 200 peer reviewed papers.
Dr. Chung received the American Academy of Pediatrics Young Investigator Award, the Medical Achievement Award from Bonei Olam, and a career development award from Doris Duke. She is a member of the Glenda Garvey Teaching Academy, and has won many awards for teaching including the Charles W. Bohmfalk Award for Distinguished Contributions to Teaching, American Medical Women’s Association Mentor Award, and Columbia University Presidential Award for Outstanding Teaching.
Vincenzo Costigliola, M.D.
Founder and President of European Medical Association
Dr. Vincenzo Costigliola received his medical degree from the university of Naples and an honors diploma in Anesthesiology and Intensive Care from the University of Pisa. In addition, Dr. Costigliola has completed studies in Rheumatology, Dermatology, Proctology, Surgery, Drug Abuse, Emergency Treatment, Disaster Action, Hospital Organization, Medical Teaching Methodology, and Computer and Audio-Visual Training for the Medical Profession.
Dr. Costigliola is President of the European Association for Predictive, Preventive, and Personalized Medicine and President of the European Depression Association. He is a Board member of the European Biotechnology Association and a member of the International Advisory Board at King Abdulaziz University in Saudia Arabia. He was selected as expert evaluator in the 5th Framework Program and is the Associate Editor of the European Association for Predictive, Preventive, and Personalized Medicine Journal.
Dr. Costigliola is fluent in Italian, French, English, and Spanish.
Staff writer, Science
Ms. Jennifer Couzin-Frankel is an award-winning staff writer at Science, where she covers an eclectic mix of stories in biomedical research in addition to pieces that examine risk in medicine and tensions in the scientific community. Several of her stories have been anthologized in Best American Science Writing. Her work has also appeared in the Washington Post, Wired, and other publications.
Ms. Couzin-Frankel has written extensively about genomics, including efforts to translate new discoveries into clinical practice. Her story, “What Would You Do?” in 2011 was among the first to examine incidental genomic findings and the debate over whether and how to share the findings with research volunteers. She has written on the subjects of volunteer privacy in genomics studies, efforts to create personalized mouse models for cancer treatment, and how preconception genetic testing is changing the experience of patients with genetic disease, among many other topics.
In the fall of 2014, Ms. Couzin-Frankel chose to be tested for BRCA mutations for personal reasons. Unexpectedly, she came face-to-face with expanded testing options for cancer risk, an experience she shared in the Sciencestory, “Unknown Significance.” She wrote: “Years of writing about genetic testing did not prepare me for my own foray into this rapidly changing world.”
Kristine Crews, PharmD
Laboratory Director, St. Jude Children’s Research Hospital
Dr. Kristine Crews is Translational Research Laboratory Director in the Pharmaceutical Sciences Department at St. Jude Children’s Research Hospital and Director of the first ASHP-Accredited PGY2 Residency in Clinical Pharmacogenetics. Dr. Crews earned both her B.S. in pharmacy, and her Pharm.D. degree from Rutgers University. She completed a pharmacy practice residency, and a clinical pharmacokinetics specialty residency at the University of Kentucky Chandler Medical Center, and completed a fellowship in clinical pharmacokinetics, and pharmacodynamics at the University of North Carolina and Glaxo Wellcome, Inc.
Her research interests include the clinical implementation of pharmacogenetics to individualize treatment regimens for children with cancer.
Joshua Denny, M.D.
Associate Professor of Biomedical Infomatics and Associate Professor of Medicine, Vanderbilt University Medical Center
Dr. Joshua Denny is an Associate Professor in the Departments of Biomedical Informatics and Medicine at Vanderbilt University Medical Center. He completed an internal medicine residency as a Tinsley Harrison Scholar at Vanderbilt.
Dr. Denny’s interests in medical informatics began while in medical school with the development of a concept-based curriculum database to improve medical education. Currently, he focuses on applications of algorithms to accurately identify phenotypes from EMR data, and utilizing this date to discover genome-phenome associations to better understand disease risk and drug response. Dr. Denny and his lab have developed the Phenome-wide Association Study method applied to EMRs to rapidly uncover genetic pleiotropy and highlight potential drivers of genetic associations with endophenotypes.
Dr. Denny helps lead efforts for local and network pharmacogenetics implementation activities including Vanderbilt PREDICT that has tested more than 14,000 individuals to provide genetic-tailored therapy recommendations. He is a member of the Electronic Medical Records and Genomics network, Pharmacogenomics Research Network, a principal investigator in the Implementing Genomics in Practice networks, and is a principal investigator of other grants exploring phenomics, EHR data mining, natural language processing, and medical education.
Dr. Denny is a past recipient of the American Medical Informatics Association New Investigator, Homer Warner award, and the Vanderbilt Chancellor Award for Research. He remains active in his clinical and teaching roles and serves on several local committees.
Nilüfer Ertekin-Taner, M.D., Ph.D.
Associate Professor, Neurology and Neuroscience, Mayo Clinic
Dr. Nilüfer Ertekin-Taner is Associate Professor of Neurology and Associate Professor of Neuroscience at Mayo Clinic. She received her M.D. from Hacettepe University Medical School in Ankara, Turkey, and her Ph.D., in Molecular Neuroscience from Mayo Graduate School. She completed her neurology residency training, and fellowship in Behavioral Neurology at Mayo Clinic.
Dr. Ertekin-Taner’s laboratory uses biological traits to uncover genetic risk factors for neurodegenerative conditions. Her research aims to discover and characterize genetic factors underlying the complex genetics of Alzheimer’s disease, and related neurodegenerative conditions. Her earlier work contributed to the establishment of the endophenotype approach in genetic studies of Alzheimer’s disease, and pioneered the use of amyloid β peptide levels as an endophenotype in AD genetic research.
Her recent scientific contributions include the completion of one of the largest expression genome-wide association studies (eGWAS) in human brains, which extensively characterized the genetics of human brain gene expression, and their role in human diseases, including Alzheimer’s disease.
An early recipient of the Translational Science KL2 award, Dr. Ertekin-Taner has been continually funded by the NIH, and numerous foundations, and currently leads multiple collaborative projects aimed at gene, and pathway discoveries in Alzheimer ’s disease, and other neurodegenerative diseases.
Gianrico Farrugia, M.D.
Vice President of Mayo Clinic and CEO, Mayo Clinic in Florida
Dr. Gianrico Farrugia completed his undergraduate training at St. Aloysius College in Birkirkara, Malta, and received his M.D. at the University of Malta Medical School in 1987.
Dr. Farrugia is Vice President of Mayo Clinic and CEO of Mayo Clinic in Florida. He is a consultant in the Division of Gastroenterology and Hepatology and the Department of Physiology and Biomedical Engineering at Mayo Clinic in Rochester, Minnesota as well as a professor of medicine and physiology in the Mayo Clinic College of Medicine. He recently served as the director of the Mayo Clinic Center for Individualized Medicine.
Dr. Farurgia's research interests include genomics, the treatment of disorders of gastrointestinal motility, mechanosensitive ion channels, ion channel regulation, and a cell type known as the interstitial cell of Cajal. He has published more than 250 articles on these topics.
Dr. Farrugia's awards include top teacher awards, Mayo Clinic Research Career Achievement Award and the Janssen Award for Outstanding Science in Gastroenterology.
Ian Foster, Ph.D.
Director of the Computation Institute & Argonne Distinguished Fellow
Dr. Ian Foster is the Arthur Holly Compton Distinguished Service Professor of Computer Science at the University of Chicago, an Argonne Distinguished Fellow at Argonne National Laboratory, and the Director of the Computation Institute, a joint unit of Argonne and the University.
He is a fellow of the American Association for the Advancement of Science, the Association for Computing Machinery, and the British Computer Society.
Dr. Foster’s research is concerned with the acceleration of discovery in a networked world.
Dr. Foster’s awards include the British Computer Society's Lovelace Medal, honorary doctorates from the University of Canterbury, New Zealand, and CINVESTAV, Mexico, and the IEEE Tsutomu Kanai award.
Stephen Friend, M.D., Ph.D.
President and Co-Founder, Sage Bionetworks
After receiving a Ph.D. in biophysics, Dr. Stephen Friend completed his clinical training at Children’s Hospital of Philadelphia and the Dana-Farber Cancer Research Institute in Boston. Dr. Friend was on the Harvard Medical School faculty from 1987-1995, Massachusetts General Hospital from 1990-1995 and University of Washington before becoming a Full Member at the Fred Hutchinson Cancer Research Center in 1995. He led the Whitehead Institute, Weinberg lab team to clone the first tumor suppressor gene p53 and characterized its role in controlling the cell cycle.
Dr. Friend and Dr. Leland Hartwell founded and co-led the 'Seattle Project', an institute that developed a method for examining large patterns of genes to provide detailed functional snapshots linking yeast and man and allowed researchers to intuit cellular activity directly from data. By 1997, the Seattle Project evolved into Rosetta Inpharmatics, a company co-founded with Dr. Leroy Hood. Rosetta developed cutting edge tools to generate and analyze high-dimensional functional genomics data, matching genetic variation and function to drug response. Merck & Company acquired Rosetta in 2001 and integrated its approach across the global pharmaceutical enterprise with Dr. Friend as Senior Vice President and Franchise Head for Oncology Research.
In 2009, Dr. Friend and Dr. Eric Schadt co-founded Sage Bionetworks, a non-profit organization with a goal to create a global integrative bionetwork community where researchers are rewarded for collaborating and sharing their data, knowledge and insights.
Dr. Friend continues to actively engage the community to crowd-source solutions to complex biomedical questions through targeted open DREAM analysis challenges.
Olga Golubnitschaja, M.D.
Head of the Division Molecular and Experimental Radiology, Department of Radiology, University of Bonn
Dr. Olga Golubnitschaja is on the medical faculty and head of the Department of Radiology of Bonn University. She has studied journalism, biotechnology and medicine and has been awarded fellowships for biomedical research in Pediatrics and Neurosciences in Austria, Russia, United Kingdom, Germany, Netherlands, and Switzerland.
Dr. Golubnitschaja is well-cited in the research fields of “gene hunting” and “subtractive hybridization” applied to predictive prenatal and postnatal diagnostics published as O.Labudova in 1990-2000. She is an expert in molecular diagnostics actively publishing in numerous fields. She is the co-founder of the Theory of Individual Patient Profiles, author of Fundamental Works in Systems Medicine - holistic approach considering molecular patterns at epi\genomic, transcriptional and post\translational levels.
Dr. Golubnitschaja holds appointments, at the rank of Professor, at several European universities and in International Programs for Personalized Medicine and has authored more than 300 international publications in the field.
Dr. Golubnitschaja is the recipient of numerous prestigious awards including the National & International Fellowship fo the Alexander von Humboldt-Foundation; Highest Prize in Medicine and Eiselsberg-Prize in Austria. She is Secretary-General of the European Association for Predictive, Preventive and Personalized Medicine and she is Advisor and Evaluator of projects dedicated to personalized medicine at the EU-Commission in Brussels, NIH/NCI, Washington D.C., and Foundations and National Ministries of Health in several European countries.
Kevin Halling, M.D., Ph.D.
Associate Professor, Mayo Clinic
Dr. Halling is Associate Professor, and Vice Chair for Research and Development for the Mayo Clinic Department of Laboratory Medicine and Director for the Clinical Molecular Genetics Laboratory which performs molecular oncology and hereditary disorder testing. He received a Ph.D. in Biochemistry, and an M.D. at the University of Kansas, and completed an Anatomic and Clinical pathology residency, and Clinical Molecular Genetics fellowship at Mayo Clinic.
Dr. Halling’s area of interest is the development of genetic tests used in the diagnosis and treatment of sporadic and hereditary cancer. He is working with a research team on the development of a clinical RNA Seq assay that can be used to detect gene fusions in patients with various types of malignancies.
Dr. Halling has published over 100 papers, many focusing on genetic testing of cancer.
Steven Joffe, M.D., MPH
Emanuel and Robert Hart Associate Professor of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine
Dr. Steven Joffe is the Emanuel and Robert Hart Associate Professor of Medical Ethics and Health Policy at the University of Pennsylvania Perelman School of Medicine. He serves as Vice-Chair of the Department, and directs the Fellowship in Advanced Biomedical Ethics. He attended Harvard College, received his M.D. from UC San Francisco, and received his MPH from UC Berkeley. Dr. Joffe trained in pediatrics at UCSF, and in pediatric hematology/oncology at the Dana-Farber Cancer Institute and Boston Children’s Hospital.
His clinical work focuses on stem cell transplantation in children. His research addresses the many ethical challenges that arise in the conduct of clinical and translational investigation. He is the principal investigator of studies that examine the roles, and responsibilities of principle investigators in multicenter randomized trials, accountability in the clinical research enterprise, return of individual genetic results to participants in cohort studies, and the integration of genomic sequencing technologies into cancer care.
Dr. Joffe serves as Chair of the Children’s Oncology Group Bioethics Committee, is a member of the U.S. Food and Drug Administration’s Pediatrics Ethics Subcommittee, and a member of the National Academy of Sciences Committee on Federal Research Regulations and Reporting Requirements.
Rima Kaddurah-Daouk, Ph.D.
Associate Professor of Psychiatry and Behavioral Sciences, Duke University
Dr. Rima Kaddurah-Daouk received a Ph.D. in biochemistry from the American University in Beirut and completed a post-doctoral fellowship at the Johns Hopkins Medical School where she worked for two years with Nobel Laureate Dr. Hamilton Smith on the mechanism of protein-DNA recognition.
A co-founder of the Avicena Group, Dr. Kaddurah-Daouk has contributed significantly to the field of energy impairment in disease through her work on the creatine kinase system. With training at Johns Hopkins, Massachusetts General Hospital, Harvard Medical School, and the Massachusetts Institute of Technology, she is credited with several breakthrough inventions that are protected by a portfolio of more than 60 patents and patent applications. A number of these patents are recognized as the industry's earliest patent filings around creatine kinase and energy impairment and neurodegenerative diseases, as well as metabolomics.
Dr. Kaddurah-Daouk serves as the president of the Metabolomics Society, is an adjunct associate professor at Duke University Medical Center and maintains a research affiliation with the Dana Farber Cancer Institute. In addition to co-founding the Avicena Group, she is also credited as a co-founder of Metabolon, another leading biotechnology company.
Dr. Kaddurah-Daouk has key scientific publications in the field of energy impairment in disease. Her collaboration with Dr. M. Flint Beal and others at Harvard Medical School resulted in scientific discoveries that confirmed both the important role of creatine kinase in neuronal cell death and the beneficial effect of creatine supplementation for the potential treatment of ALS and other neurodegenerative diseases.
Konstantinos Lazaridis, M.D.
Professor of Medicine and Consultant in the Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine
Dr. Konstantinos Lazaridis is a Professor of Medicine and a Consultant in the Division of Gastroenterology and Hepatology at Mayo Clinic College of Medicine.
Dr. Lazaridis received his medical degree at the University of Ioannina in Greece. He completed his Internal Medicine and Gastroenterology fellowship training at Mayo Clinic and was a Mayo Clinic Scholar in Genomics in the laboratory of Dr. Francis Collins at the National Human Genome Research Institute.
Dr. Lazaridis is considered a leader in the area of the genomics of chronic cholestatic liver diseases, namely, Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Since 2003, he has established and is the principal investigator of the two national consortia for studying patients afflicted with these diseases. Supported by the NIH, Dr. Lazaridis and his research group apply the latest genomic and genetic epidemiology approaches to better understand these diseases and treatment methods.
As Associate Director of the Center for Individualized Medicine in Rochester, Dr. Lazaridis has been instrumental in the establishment and expansion of the Individualized Medicine Clinic and the direction of the Clinomics Translational Program.
Joshua Lewis, Ph.D.
Assistant Professor, University of Maryland School of Medicine
Dr. Joshua Lewis is an assistant professor in the Division of Endocrinology, Diabetes, and Nutrition as well as the Program for Personalized and Genomic Medicine at the University of Maryland School of Medicine. He received his Ph.D. in Molecular Genetics and Genomics at the Center of Genomics and Personalized Medicine Research at Wake Forest University.
Dr. Lewis’s research is identifying and functionally characterizing genes contributing to cardiovascular disease risk and translating genetic discoveries into individualized patient care through pharmacogenomics and/or other clinical approaches. His recent research has shown genetic variants in the Platelet Endothelial Aggregation Receptor 1 (PEARt) gene are associated with platelet reactivity and cardiovascular outcomes in patients on aspirin therapy. He is currently exploring the functional consequences of these polymorphisms in cellular models as well as in human populations.
Dr. Lewis is a member of the NIGMS-funded Pharmacogenomics Research Network and Pharmacometabolomics Research Network. He is the principal investigator of a Translational Scholar Career Award in Pharmacogenomics and Personalized Medicine to investigate the genetic underpinnings and mechanisms underlying aspirin and clopidogrel resistance as well as determining optimal antiplatelet dosing.
His honors include an NIH Extramural Clinical Research LRP Award, a Trainee Research Award from the American Society of Human Genetics, and a Training Fellowship in Cardiovascular Cell Biology from the National Heart, Lung, and Blood Institute.
Noralane Lindor, M.D.
Professor of Medical Genetics, Mayo Clinic
Dr. Noralane Lindor received her M.D. from Mayo Medical School, and trained and practiced as a Family Medicine physician. She completed training in clinical, and molecular genetics, and held positions as clinical geneticist, educator, and researcher in the Department of Medical Genetics at Mayo Clinic in Minnesota Rochester, and since 2012, as researcher in the Department of Health Sciences Research at Mayo Clinic in Arizona.
Dr. Lindor’s research focus has included exploring the feasibility, and impact of integration of new genetic sequencing technologies into the clinical practice.
She has published extensively across a broad range of genetic topics including syndromology and chromosomal disorders, and is best known for her works on the recognition, and risk management of hereditary cancer syndromes.
Edison Liu, M.D.
President and CEO, Jackson Laboratory
Dr. Edison Liu obtained his B.S. in chemistry and psychology, as well as his M.D., at Stanford University.
Dr. Liu was the founding executive director of the Genome Institute of Singapore and President of the Human Genome Organization from 2007-2013. He held leadership positions as the Scientific Director of the National Cancer Institute's Division of Clinic Sciences, the director of the UNC Lineberger Comprehensive Cancer Center's Specialized Program of Research Excellence in Breast Cancer, the director of the Laboratory of Molecular Epidemiology at UNC's School of Public Health, chief of medical genetics, and Chair of the Correlative Science Committee of the National Cooperative Clinical Trials Group.
Dr. Liu is an international expert in cancer biology, genomics, human genetics, molecular epidemiology, and translational medicine. He served as Chairman of the Board of Singapore's Health Sciences Authority from 2007-2012 which is the Drug Regulatory Agency for the nation.
He is the recipient of the President's Medal of Singapore for his work to help resolve the SAR's crisis in Singapore and he has authored over 300 scientific papers and reviews, and co-authored two books.
Dr. Liu's current scientific research is focused on the functional genomics of human cancers, particularly breast cancer, uncovering new oncogenes, and deciphering the dynamics of gene regulation on a genomic scale that modulate cancer biology.
Patricia LoRusso, D.O.
Associate Director of Innovative Medicine, Professor of Medicine, Yale Cancer Center
Dr. Patricia LoRusso received her D.O from the Michigan State University School of Osteopathic Medicine and completed a fellowship in Medical Oncology with a focus on developmental therapeutics. She joined the faculty at Wayne State University School of Medicine in 1988. As a result of her focus on early therapeutics, she has come to be recognized as an international expert in the field of Phase 1 clinical research with a focus on novel trial design.
Recently, Dr. LoRusso joined Yale Cancer Center as a Professor of Medicine and Associate Director of Innovative Medicine. She has served as co-chair of the National Cancer Institute’s Cancer Therapy Evaluation Program Investigational Drug Steering Committee. She has served on the scientific committees of the American Society of Clinical Oncology, numerous peer-reviewed study sections, and NCI committees.
Dr. LoRusso has garnered many awards including the American College of Osteopathic Internists Researcher of the Year Award and the Hero of Breast Cancer award. In 2008, she was named one of Crain’s Detroit Business Health Care Heroes, was recognized with the Michaele C. Christian Oncology Drug Development Award and Lectureship from NCI CTEP.
Dr. LoRusso is a former editor of Investigational News Drugs, is currently on the editorial board for Clinical Cancer Research, and is a reviewer for several journals. She has authored more than 200 articles on cancer research in peer-reviewed journals, and written multiple book chapters.
Elizabeth Mansfield, M.D., Ph.D.
Deputy Director for Personalized Medicine, Office of In Vitro Diagnostics and Radiological Health, Center for Devices and Radiological Health
Dr. Elizabeth Mansfield received her Ph.D., from Johns Hopkins University and completed postdoctoral training at the National Cancer Institute and the National Institute for Arthritis, Musculoskeletal, and Skin Diseases.
Dr. Mansfield has extensive experience in regulation and policy regarding in vitro diagnostic devices where she is developing a program to address companion and novel diagnostic devices. In addition, she has led the development of a personalized medicine program in CDRH.
Previously, Dr. Mansfield served as the Director of Regulatory Affairs at Affymetrix, Inc., 2004-2006, along with Scientific Reviewer, and Genetics Expert.
Jennifer McCormick, M.D., Ph.D.
Assistant Professor of Biomedical Ethics, Mayo Clinic
Dr. Jennifer McCormick is an Assistant Professor of Biomedical Ethics in the Departments of Medicine and Health Sciences Research. She received her doctorate degree in molecular and cellular biology. She received her Master’s degree in public policy from the University of Michigan. Before coming to Mayo Clinic in 2008, she was a fellow at the Stanford Center for Biomedical Ethics.
Dr. McCormick lectures frequently on topics related to research and translational ethics and directs Mayo Clinic’s graduate school course on Responsible Conduct of Research. She is a primary consultant on the CCaTs Clinical and Translational Research Ethics Consultation Service and works closely with clinical investigators and the IRB to enhance the quality of Mayo Clinic’s research protections.
Dr. McCormick’s scholarly interests focus on topics in research ethics and scientists understandings of policy and social responsibility in context of their work. She has published on topics related to research ethics consultation, genetic and genomic research and biobanking, human research participant engagement and protection, and challenges in translational research.
Dr. McCormick works closely with the Mayo Clinic Center for Individualized Medicine.
Grzegorz Nowakowski, M.D.,
Assistant Professor of Medicine, Mayo Clinic College of Medicine
Dr. Grzegorz Nowakowski is a Consultant and Chair of Education in the Division of Hematology at Mayo Clinic, an Assistant Professor of Medicine in Mayo Clinic College of Medicine, and program director of the Hematology/Oncology Fellowship in Mayo School of Graduate Medical Education.
He received his M.D. from the Medical University of Warsaw in Poland. He completed his internal medicine residency at Norwalk Hospital in Norwalk, Conn., and his fellowship in hematology-oncology at Mayo Clinic. Dr. Nowakowski joined the Mayo Clinic lymphoma group in 2006 as a Mayo Foundation Scholar.
His research focuses on molecular classification, biology, and novel therapies of lymphoproliferative disorders. He is the principal investigator of multiple investigator-initiated, and cooperative group clinical trials, and serves as scientific officer in the Academic and Community Cancer Research United where he is responsible for overseeing hematology clinical trials.
Dr. Nowakowski chaired the American Society of Clinical Oncology Lymphoma and Myeloma Education Committee for 2014-2015. He is an alumnus of the American Society of Hematology Clinical Research Training Institute, and served as a member of the ASH Committee on Scientific Affairs.
Tamas Ordog, M.D.
Associate Professor, Physiology, Mayo Clinic
Dr. Tamas Ordog is a Consultant and Associate Professor in the Department of Physiology and Biomedical Engineering and the Division of Gastroenterology and Hepatology at Mayo Clinic and founding Director of the Epigenomics Program of the Mayo Clinic Center for Individualized Medicine. He received predoctoral training in molecular endocrinology at the University of Pees, Hungary and postdoctoral training in integrative neuroendocrinology at the University of Texas Houston Health Science Center.
Dr. Ordog has studied the cellular and molecular basis of gastrointestinal neuromuscular control in health and disease since 1998. His current research interests include the epigenetic control of cellular phenotypes in the lineage of gastrointestinal pacemaker/neuromodulator cells in aging, diabetes, and caloric restriction and oncogenesis in response to targeted oncolytic therapy.
As Director of the Mayo Clinic CIM Epigenomics Program, he is leading the effort to implement epigenomic testing in the Individualized Medicine Clinic.
Eric Pamer, M.D.
Chief, Infectious Disease Service, Memorial Sloan-Kettering Cancer Center
Dr. Eric Pamer received his medical degree from Case Western Reserve University Medical School and completed clinical training in Internal Medicine and Infectious Diseases at UCSD Medical Center. Before moving to Yale University, he was a postdoctoral fellow with Charles E. Davis at UCSSD, Maggie So at Scripps Research Institute and Michael Bevan at the University of Washington.
In 2000, Dr. Pamer moved his laboratory to Memorial Sloan-Kettering Cancer Center in New York where he has been Chief of Infectious Disease and, more recently, Head of the Division of General Medicine.
Mrinal Patnaik, MBBS
Consultant and Assistant Professor of Oncology and Internal Medicine and Consultant in the Division of Hematology, Mayo Clinic
Dr. Mrinal Patnaik is a Consultant in the Division of Hematology and the Department of Internal Medicine at Mayo Clinic. He serves as a clinical consultant in hematological malignancies, and allogeneic stem cell transplantation, and is the current program director for the Bone Marrow Transplant Fellowship. He is the Myeloid Director for the Mayo Clinic Center for Individualized Medicine, and has a special interest in epigenetic dysregulation in myeloid malignancies.
Dr. Patnaik received his MBBS from Grant Medical College in India. He completed an internal medicine residency at the University of Minnesota, and a Fellowship in Hematology, Oncology and Bone Marrow Transplant at Mayo Clinic.
Dr. Patnaik has authored numerous publications on myeloid neoplasms, with particular focus on myelodysplastic Syndromes, and chronic myelomonocytic leukemia. He has documented the adverse prognostic impact of ASXL1 gene mutations in myeloid neoplasms. This seminal work has resulted in the development of the Molecular Mayo Prognostic model for patients with CMML.
He received the CTSA KL2 award for furthering his training in epigenetics, and cancer biology and the Margret Landenberg Foundation award for studying the effect of oncolytic viruses in blood cancers.
Katherine Payne, Ph.D.
Professor of Health Economics, Manchester Center for Health Economics
Ms. Katherine Payne received her clinical pharmacy degree from Keel University, her Master of Science in Health Economics degree from York University, and her Doctor of Philosophy in Pharmacy Practice degree from Manchester University. She served as the health economist for the North West Genetics Knowledge Park (Nowgen) between 2003 and 2007, and in 2010 was awarded a personal chair in health economics at The University of Manchester.
Ms. Payne was awarded a five-year Research Councils UK Academic Fellowship in Health Economics to focus on the evaluation and valuation of genomic technologies including genomic-based diagnostics, and pharmacogenetic tests. Her recent projects include: evaluating an integrated model of service delivery for inherited retinal dystrophies, economic evaluation of personalized breast screening programs, preliminary economic evaluation of high-throughput whole genome sequencing technologies, economic evaluations of different applications of pharmacogenetic testing, and the application of stated preference methods, including discrete choice experiments.
Ms. Payne was a member of a NICE Technology Appraisal Committee. She holds honorary positions with the School of Pharmacy, University of Nottingham, PHG Foundation, Cambridge, Central Manchester University Hospitals NHS Foundation Trust, and Nowgen, Manchester.
Naveen Pereira, M.D., F.A.C.C.
Assistant Professor, Medicine and Pharmacology, Mayo Clinic College of Medicine
Dr. Naveen Pereira is a Consultant for the Division of Cardiovascular Diseases and Assistant Professor of Medicine and pharmacology, Mayo Clinic College of Medicine. He is board certified in Internal Medicine, cardiovascular diseases and advanced heart failure and transplant.
Dr. Pereira earned his medical degree at University of Bombay. He completed his internship and residency at the University of Connecticut and cardiac fellowship at the Brown University Hospital System and Massachusetts General Hospital.
Dr. Pereira received the Mayo Clinic Department of Medicine Career Development Award, the Marie Ingalls Cardiovascular Career Development Award, the Academic Research in Cardiology Award, the Transplant Center Scholarly Program Award, the Clinical Immunology and Immunotherapeutic Program Award and the Clinical and Translational Sciences KL2 Award with a focus on translating the genetics of pharmacotherapy.
Dr. Pereira served as Chairperson of the Standards and Guidelines Workforce of the International Society of Heart and Lung Transplantation. He is a member of the Functional Genomics and Translational Biology Council of the American Heart Association and is a member of the Circulation: Cardiovascular Genetics editorial board.
Dr. Pereira’s research interest include treatment of end-stage heart failure, antibody-mediated rejection in heart transplant, cardiac allograft hypertrophy, and genetics of the natriuretic peptide system and pharmacogenomics.
Kathryn Phillips, Ph.D.
Professor, School of Pharmacy, University of California, San Francisco
Dr. Kathryn Phillips is the founding director of the Center for Translational and Policy Research on Personalized Medicine in the School of Pharmacy at the University of California, San Francisco. She is also a professor of health economics, and health services research in the Department of Clinical Pharmacy with additional appointments in the Philip R. Lee Institute for Health Policy Studies, and Helen Diller Family Comprehensive Cancer Center.
Dr. Phillips is a health services researcher, health economist, and leader in the application of new technologies to improve health care. Her focus is on issues around access, quality, and value of new technologies. Her core specialty is personalized medicine with her work spanning multiple disciplines, including basic, clinical, and social sciences, and mobilizing experts in academia, industry, health care, payers, and government.
She led one of the earliest studies on pharmacogenomics, underscoring its potential to reduce the incidence of adverse drug reactions (JAMA, 2001), and her analysis of HIV home testing informed the FDA’s decision to approve the first home collection HIV test (New England Journal of Medicine, 1995).
Dr. Phillips has served on national and international scientific advisory committees, and workshops including work for GenomeCanada, Institutes of Medicine, Food and Drug Administration, Centers for Disease Control and Prevention, and the President’s Council of Advisors on Science and Technology. She has served as an advisor to various international, and industry organizations, including more than 35 biotechnology companies, and venture capital firms.
She is a member of the editorial board of the journal Health Affairs, and several leading journals on personalized medicine. She has published more than 100 peer-reviewed articles in major journals, including JAMA, the New England Journal of Medicine, and Health Affairs.
For more than 25 years, Dr. Phillips has received funding from the US. National Institutes of Health as a principal investigator.
Eric Reiman, M.D.
Professor of Psychiatry, University of Arizona
Dr. Eric Reiman is Executive Director of the Banner Alzheimer’s Institute, Chief Executive Officer of Banner Research, Professor of Psychiatry at the University of Arizona, University Professor of Neuroscience at Arizona State University, Clinical Director of Neurogenomics at the Translational Genomics Research Institute, and Director of the Arizona Alzheimer’s Consortium.
Dr. Reiman received his undergraduate and medical degrees at Duke University. He completed his psychiatry residency training at Duke University and Washington University and his introduction to brain imaging research at Washington University.
Dr. Reiman is internationally recognized for his contributions to brain imaging research, the behavioral neurosciences, and the presymptomatic study of Alzheimer’s disease. He has developed a strategy to find demonstrably effective treatment to prevent Alzheimer’s disease.
Dr. Reiman has authored more than 250 publications. He is a principal investigator of several NIH-supported research programs, and a leader of the Alzheimer’s Prevention Initiative.
Veronique Roger, M.D.
Professor of Epidemiology and Professor of Medicine, Mayo Clinic
Dr. Veronique Roger received her M.D., from the Paris, France Medical School and her M.P.H., from the Minnesota School of Public Health. At Mayo Clinic, she is a Professor of Internal Medicine, a Professor of Epidemiology, a cardiologist, an epidemiologist, and an outcomes researcher.
Dr. Roger’s research program focusing on the occurrence and outcomes of cardiovascular diseases is closely linked with the internationally recognized Rochester Epidemiology Project, and has been funded by the NIH since 1996.
Dr. Roger serves in several leadership roles within Mayo Clinic and is a member of the Mayo Clinic Board of Governors and Board of Trustees. In her role as Director of the Mayo Clinic Center for the Science of Health Care Delivery, Dr. Roger oversees several initiatives relevant to the research use of clinical data in the electronic health record environment including the Rochester Epidemiology Project and the High Value Health Care Collaborative.
Dr. Roger serves on national committees and task forces at the American Heart Association, the Institute of Medicine and the National Institutes of Health where she is a member of the National Heart, Lung and Blood Advisory Council.
Sushmita Roy, Ph.D.
Assistant Professor, Biostatistics and Medical Informatics and Wisconsin Institute for Discovery, University of Wisconsin
Dr. Sushmita Roy is an assistant professor in the Department of Biostatistics and Medical Informatics and the Wisconsin Institute for Discovery at the University of Wisconsin. She received her Ph.D. from the University of New Mexico, and a post-doctorate degree at the Broad Institute of MIT and Harvard.
Dr. Roy’s lab focuses on the development, and application of statistical machine learning methods to problems in regulatory genomics. Particular focus is placed on building network-based predictive models in developmental, and evolutionary lineages.
Dr. Roy received the 2014 Alfred P. Sloan Foundation Fellowship award, and an NSF CAREER award.
Richard Sharp, Ph.D.
Director of Biomedical Ethics, Mayo Clinic
Dr. Richard Sharp is Director of Mayo Clinic’s Biomedical Ethics Program. Prior to joining Mayo Clinic, he was Director of Bioethics Research at Cleveland Clinic, and Co-Director of the Center for Genetic Research Ethics and Law at Case Western Reserve University, one of six NIH Centers of Excellence in Ethics Research.
Dr. Sharp’s current research includes examining how patients, and health care providers view new forms of personalized medicine, and clinical interventions enabled by molecular diagnosis.
He frequently advises health care organizations on ethical issues, and has served on advisory committees for the National Institutes of Health, Institute of Medicine, American College of Medical Genetics, and the US Environmental Protection Agency.
Dr. Sharp is widely published on topics in biomedical ethics, including clinical ethics consultation, informed consent, financial conflicts of interest, and ethical tensions in patient advocacy.
Raul Urrutia, M.D.
Professor of Biophysics, Mayo Clinic
Dr. Raul Urrutia is Professor of Medicine, Biochemistry and Molecular Biology, and Biophysics at Mayo Clinic. He graduated Magna Cum Laude in 1987 from Cordoba University Argentina and pursued postdoctoral training at the National Institues of Health in Bethesda Maryland.
Dr. Urrutia established a laboratory at Mayo Clinic dedicated to studying chromatin dynamics and epigenetics as applied to metabolism and cancer. His laboratory discovered several HDAC, HATs, and HMTs pathways that associate with the development of diabetes and pancreatic cancer. His current work is focused on the functional characterization of HMT pathways, in particular G9a, GLP, SUV39H1, and EZH2.
Dr. Urrutia has published highly influential original articles, book chapters, reviews, and a widely cited textbook on pancreatic cancer. He has served as the Editor-in-Chief for three journals, Pancreatology, International Journal of Gastrointestinal Cancer, and Case Reports in Gastroenterology. He is a member of several editorial boards including the Journal of Biological Chemistry, Medical Epigenetics, and Pancreatology and Pancreas.
Dr. Urrutia served as President for the American Pancreatic Association, Chair for Pancreatic Diseases Section for the American Gastroenterological Association, and Chair for the International Association of Pancreatology board.
J. Craig Venter, Ph.D.
Co-Founder, Executive Chairman, and CEO of Human Longevity Inc., J. Craig Venter Institute, and Synthetic Genomics
Dr. J. Craig Venter is a co-founder, executive chairman and CEO of Human Longevity Inc, a privately held genomics, and cell therapy-based diagnostic, and therapeutic company focused on extending the healthy, high performance human life span. He is also founder, executive chairman, and CEO of the J. Craig Venter Institute, and a co-founder, executive chairman, and co-chief scientist of Synthetic Genomics Inc., a privately held company focused on developing products, and solutions using synthetic genomic technologies.
Dr. Venter is renowned for his contributions in sequencing the first draft human genome in 2001, the first complete diploid human genome in 2007, and construction of the first synthetic bacterial cell in 2010.
Currently, he and his teams are focused on a variety of projects, and programs including: synthetic genomic research, and the application of these advances to develop new vaccines, and food and nutritional products, new biofuels, and biochemicals; continued analysis of the human genome including the human microbiome, and discovering, and understanding genetic diversity in the world's oceans.
Dr. Venter is a recipient of the 2008 National Medal of Science, and is a member of the National Academy of Sciences.
He is the author of Life at the Speed of Light: From the Double Helix to the Dawn of Digital Life (Viking, 2013), and A Life Decoded: My Genome: My Life (Viking, 2007).
Liewei Wang, M.D., Ph.D.
Professor of the Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic
Dr. Liewei Wang is a Professor of the Department of Molecular Pharmacology and Experimental Therapeutics at Mayo Clinic. She received her M.D. from FuDan University, Shanghai, China, and a PhD., with an emphasis on cancer biology, and cancer pharmacology, from the Mayo Graduate School.
Dr. Wang has developed a research program with a focus on the use of high throughput genomic technology including array based and next generation sequencing methods, joined with a cell-based model system that consists of 300 lymphoblastoid cell lines, to study mechanisms of cancer biology, and antineoplastic drug resistance, both chemotherapy and radiation therapy.
In addition to her career-long involvement in pharmacogenomics, Dr. Wang has extensive experience in functional genomics. She is involved in many clinical translational studies which help identify, and understand biomarkers associated with clinical response to endocrine therapy, and chemotherapy in breast cancer patients.
Dr. Wang is a member of several key programs at Mayo including: the Mayo-NIH Comprehensive Cancer Center, and the Mayo Center for Individualized Medicine. She is also Co-Principal Investigator, and the leader of the Functional Genomics Group for the Mayo-NIH Pharmacogenetics Research Network, and the Associate Director for the Pharmacogenomics Program in the Mayo CIM.
David Weinstock, M.D.
Associate Professor Medicine, Dana-Farber Cancer Institute and Harvard Medical School
Dr. David Weinstock is an Associate Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School and director of the Dana-Farber hematologic malignancies patient-derived xenograft effort.
Dr. Weinstock’s clinical expertise is in the care of patients undergoing hematopoietic cell transplantation. His laboratory investigates the pathogenesis, and targeting of lymphoid malignancies.
Jieping Ye, Ph.D.
Associate Professor, University of Michigan
Jieping Ye is an Associate Professor of Department of Computational Medicine and Bioinformatics and Department of Electrical Engineering and Computer Science at the University of Michigan. He received his Ph.D. degree in Computer Science from the University of Minnesota.
His research interests include machine learning, data mining, and biomedical informatics.
Dr. Ye serves as a PC Co-Chair of SDM 2015 in addition to an Action/Associate Editor of Data Mining and Knowledge Discovery, IEEE Transactions on Knowledge and Data Engineering, and IEEE Transactions on Pattern Analysis and Machine Intelligence. He has served as Senior Program Committee/Area Chair/Program Committee Vice Chair of the NIPS, ICML, KDD, IJCAI, ICDM, SDM, ACML, and PAKDD conferences.
Dr. Ye received the NSF CAREER Award in 2010. His papers have been selected for the outstanding student paper at ICML in 2004, the KDD best research paper honorable mention in 2010, the KDD best research paper nomination in 2011, and 2012, the SDM best research paper runner up in 2013, the KDD best research paper runner up in 2013, and the KDD best student paper award in 2014.